✦ LIBER ✦

Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma

✍ Scribed by Oliver Weigert; Tim Illidge; Wolfgang Hiddemann; Martin Dreyling

Book ID: 102108590
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 306 KB
Volume: 107
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.22066

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P166 Experience with the use of yttrium-

P166 Experience with the use of yttrium-90 ibritumomab tiuxetan (Zevalin) in relapsed follicular lymphoma

✍ J. Demeter; K. Balassa; M. D¨om¨ot¨or; M. Egyed; Z. Gasztonyi; H. Aryab; M. Gurz 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB

cursor was set to the same position in each sample, where 5% of T/NK cells were Zap-70 negative. Zap-70 and CD38 labeling was determined on CD19+ cells. Results: With dichotomized evaluation of CD38 and Zap-70 expression 70% of the cases showed concordant results: 32% were Zap-70+/CD38+ and 38% were

Study of radiolabeled indium-111 and ytt

Study of radiolabeled indium-111 and yttrium-90 ibritumomab tiuxetan in primary central nervous system lymphoma

✍ Fabio M. Iwamoto; Jazmin Schwartz; Neeta Pandit-Taskar; Scott Peak; Chaitanya R. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 205 KB 👁 2 views

## Abstract ## BACKGROUND. Therapeutic options for refractory or recurrent primary central nervous system lymphoma (PCNSL) are limited. The blood–brain barrier makes many agents used in systemic lymphomas ineffective in CNS lymphomas. The objective of this study was to determine whether intravenou

Radioisotopic Localization of90Yttrium–I

Radioisotopic Localization of90Yttrium–Ibritumomab Tiuxetan in Patients with CD20+ Non-Hodgkin’s Lymphoma

✍ S. A. Jacobs; A. M. Harrison; S. H. Swerdlow; K. A. Foon; N. Avril; N. Vidnovic; 📂 Article 📅 2008 🏛 Springer-Verlag 🌐 English ⚖ 589 KB

Clinical outcomes of post-remission ther

Clinical outcomes of post-remission therapy using90yttrium ibritumomab tiuxetan (Zevalin®) for high-risk patients with diffuse large B-cell lymphoma

✍ Eun Ji Han; Sung-Eun Lee; Sung Hoon Kim; Hyung Sun Sohn; Seung Eun Jung; Gyeongs 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 313 KB

Biodistribution, radiation dosimetry and

Biodistribution, radiation dosimetry and scouting of90Y-ibritumomab tiuxetan therapy in patients with relapsed B-cell non-Hodgkin’s lymphoma using89Zr-ibritumomab tiuxetan and PET

✍ Saiyada N. F. Rizvi; Otto J. Visser; Maria J. W. D. Vosjan; Arthur van Lingen; O 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 284 KB

Consensus conference on the use of 90-yt

Consensus conference on the use of 90-yttrium-ibritumomab tiuxetan therapy in clinical practice. A project of the Italian Society of Hematology

✍ Umberto Vitolo; Giovanni Barosi; Stefano Fanti; Alessandro M. Gianni; Maurizio M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 161 KB 👁 2 views

90-yttrium-ibritumomab-tiuxetan is approved for treatment of rituximab-relapsed/refractory CD201 follicular B-cell lymphoma and as consolidation therapy in untreated follicular lymphoma. Recommendations on the use of 90-yttrium-ibritumomab tiuxetan were issued in a consensus conference, sponsored by